<DOC>
	<DOC>NCT00255255</DOC>
	<brief_summary>This study is to confirm the safety of Symbicort® Turbuhaler® 160/4.5 µg 1, 2 or 4 inhalation b.i.d. over a 52 week treatment period in asthmatic patients who are being treated with IGCS and long acting β2-agonist (LABA) and/or other anti-asthmatic drugs.</brief_summary>
	<brief_title>Safety &amp; Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Diagnosis of asthma with a documented history of at least 6 months duration prior to Visit 1 Prescribed daily use of an IGCS for ≥12 weeks prior to Visit 1 Prescribed daily use of at least one of the following: Theophylline, long acting β2agonist (LABA), other antiasthmatic drugs (leucotrine antagonists, inhaled anticholinergics, Th2 cytokine inhibitor) for at least 4 weeks prior to Visit 1 at a constant dose Any significant disease or disorder that may jeopardize the safety of the patient Respiratory infection, judged by the investigator(s) as an infection affecting the asthma, within 4 weeks prior to Visit 1 Treatment with oral, parenteral or rectal GCS within 4 weeks prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
</DOC>